INDOUS - Indo US Bio-Tech
📢 Recent Corporate Announcements
Indo Us Biotech Limited has issued a clarification to the BSE and NSE regarding recent significant fluctuations in its share price. The company stated that it is not aware of any undisclosed price-sensitive information or pending announcements that could impact trading volumes or prices. Management maintains that the current price movement is purely market-driven and based on investor sentiment. The company reaffirmed its commitment to making all necessary disclosures under Regulation 30 of SEBI LODR Regulations.
- Responded to stock exchange queries dated March 10, 2026, regarding unusual price movement
- Confirmed no material information or price-sensitive announcements are being withheld
- Attributed recent volatility to market forces and investor sentiment rather than internal developments
- Reiterated compliance with SEBI Listing Obligations and Disclosure Requirements (LODR) 2015
Indo Us Biotech Limited has addressed a clarification request from the National Stock Exchange regarding its financial results for the quarter ended September 30, 2025. The discrepancy involved the incorrect selection of reporting parameters in the XBRL filing utility. The company resubmitted the corrected filing on November 29, 2025, and provided additional responses to follow-up queries in February 2026. This matter is purely administrative and does not alter the financial figures previously disclosed to shareholders.
- NSE flagged discrepancies in the XBRL filing for the quarter ended September 30, 2025, regarding reporting types.
- The company resubmitted the revised XBRL data on November 29, 2025, to rectify the technical filing error.
- A follow-up query received on February 10, 2026, was addressed by the company on February 14, 2026.
- The clarification ensures compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Indo Us Bio Tech Limited has submitted its integrated financial filing for the quarter and nine-month period ending December 31, 2025. The submission follows the latest SEBI (LODR) Third Amendment Regulations of 2024 and specific circulars from December 2024 and January 2025. While the cover letter confirms the filing, the detailed financial performance metrics are contained within the attached report. This disclosure is a critical regulatory requirement for maintaining transparency with shareholders regarding the company's mid-fiscal year performance.
- Financial results submitted for the quarter ended December 31, 2025.
- Financial results submitted for the nine-month period ended December 31, 2025.
- Compliance maintained with SEBI Circular SEBI/HO/CFD/CFD-oD2/CIR/P/2024/185.
- Adherence to BSE Circular 20250102-4 and NSE Circular NSE/CML/2025/02 dated January 2, 2025.
- Full financial reports made available on the company's official website and exchange portals.
Indo Us Biotech Limited's Board of Directors met on January 21, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The board also reviewed and approved the limited review reports provided by the company's auditors. The meeting was brief, lasting only 20 minutes, indicating a standard procedural approval of the quarterly figures. Investors should now analyze the detailed financial statements to assess the company's performance trajectory for the fiscal year.
- Board approved unaudited financial results for the quarter ended December 31, 2025
- The board meeting was conducted on January 21, 2026, from 14:20 PM to 14:40 PM
- Limited review reports from the statutory auditors were obtained and approved by the board
- The filing was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015
Indo Us Biotech Limited's Board of Directors met on January 21, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The board also reviewed and accepted the limited review reports provided by the statutory auditors. The meeting was conducted efficiently, lasting only 20 minutes from 14:20 to 14:40. This announcement confirms the completion of regulatory requirements for the third quarter of the fiscal year.
- Approval of unaudited financial results for the quarter ended December 31, 2025
- Limited review reports from auditors were considered and approved by the board
- Board meeting concluded within a 20-minute window (14:20 PM to 14:40 PM)
- Compliance maintained under Regulation 30 of SEBI Listing Obligations
Indo Us Biotech Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the period ended December 31, 2025. The certificate, provided by Bigshare Services Private Limited, confirms that no securities were received for dematerialization during the quarter. As a result, no certificates were mutilated or cancelled, and no changes were made to the register of members. This is a standard administrative filing required by Indian market regulators.
- Compliance certificate filed for the quarter ended December 31, 2025.
- Registrar and Share Transfer Agent (RTA) Bigshare Services confirms zero dematerialization requests.
- No certificates were mutilated or cancelled during the reporting period.
- The filing ensures adherence to SEBI (Depositories and Participants) Regulations, 2018.
Indo Us Biotech Limited has notified the exchanges about the closure of its trading window starting January 1, 2026. This closure is mandatory under SEBI regulations for the upcoming announcement of unaudited financial results for the quarter ending December 31, 2025. The restriction applies to all designated persons and will lift 48 hours after the results are disclosed. The board meeting date for result approval is yet to be finalized and will be communicated separately.
- Trading window for designated persons closed effective January 1, 2026.
- Closure pertains to the unaudited financial results for the quarter ended December 31, 2025.
- Restriction remains in place until 48 hours post-result announcement.
- Complies with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Indo Us Biotech Limited has received a summons from the Directorate of Enforcement (ED), Raipur Zonal Office, under the Prevention of Money Laundering Act (PMLA), 2002. The summons, dated November 20, 2025, requires the Principal Officer to appear and produce specific documents for an ongoing investigation. Although received via email on November 27, 2025, the company only disclosed this to the exchanges on December 29, 2025. While the management claims no immediate material impact, the nature of the investigation and the significant delay in reporting are concerning for shareholders.
- Summons issued under Section 50(2) and 50(3) of the Prevention of Money Laundering Act (PMLA), 2002.
- The summons (No. PMLA/SUMMON/RPZO/2025/1983) requires appearance of the Principal Officer and production of documents.
- Significant disclosure delay: Summons received on Nov 27, 2025, but reported to exchanges only on Dec 29, 2025.
- Company attributes the delay to internal review and legal assessment processes.
- Management states there is no immediate material impact on financial or operational activities.
Financial Performance
Revenue Growth by Segment
The company reported a standalone total income of INR 3,087.27 Lakhs for Q2 FY26, representing a growth of 39.14% YoY compared to INR 2,218.79 Lakhs in Q2 FY25. For the half-year ended September 30, 2025, revenue reached INR 6,164.38 Lakhs, up 31.34% from INR 4,693.36 Lakhs in H1 FY25.
Geographic Revenue Split
Not explicitly disclosed in percentage terms, but the company is headquartered in Ahmedabad, Gujarat, and is expanding its footprint through participation in the APSA Seed Congress 2025 to target global export markets.
Profitability Margins
Net Profit Margin for Q2 FY26 stood at 11.18%, a contraction from 19.65% in Q2 FY25. Net profit for Q2 FY26 was INR 345.21 Lakhs, down 20.81% YoY from INR 435.95 Lakhs, despite the revenue increase, suggesting significantly higher operational or input costs.
EBITDA Margin
Profit Before Tax (PBT) margin for Q2 FY26 was 11.53% (INR 355.89 Lakhs) compared to 20.04% (INR 444.58 Lakhs) in Q2 FY25, reflecting a decline in core operational profitability of approximately 851 basis points.
Capital Expenditure
Historical equity share capital remains stable at INR 2,005.20 Lakhs. Other equity (excluding revaluation reserves) was reported at INR 5,846.65 Lakhs as of March 31, 2025.
Credit Rating & Borrowing
Not disclosed in available documents; however, the company maintains a paid-up equity share capital of INR 2,005.20 Lakhs with a face value of INR 10 per share.
Operational Drivers
Raw Materials
Specific raw materials include parent seeds, foundation seeds, and agricultural inputs required for hybrid seed production, which constitute the primary cost of goods sold.
Import Sources
Primary sourcing and production activities are centered in Gujarat, India, with the registered office located in Ahmedabad.
Key Suppliers
Key related party suppliers and entities include Shree Patel Beej Nigam, Indo US Agriseeds Pvt. Ltd., Patel Beej Nigam, and Agri Pari E Commerce Pvt Ltd.
Capacity Expansion
The company is a DSIR-registered research-based seed entity. While specific MT capacity is not disclosed, it is actively showcasing new high-yield hybrid and research-based varieties at international forums like the APSA Seed Congress 2025.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but the decline in net profit despite a 39% revenue jump in Q2 FY26 indicates a sharp rise in procurement or production costs.
Manufacturing Efficiency
Efficiency is driven by DSIR-registered R&D activities, focusing on high-yield varieties to improve output per acre for end-users.
Logistics & Distribution
Distribution is handled through a network of vendors and partners, including Agri Pari E Commerce Pvt Ltd for digital/modern trade reach.
Strategic Growth
Expected Growth Rate
31%
Growth Strategy
Growth is targeted through participation in the APSA Seed Congress 2025 to secure global partners and expand exports. The strategy focuses on launching high-yield hybrid varieties and leveraging its DSIR-registered R&D status to gain market share in the research-based seed segment.
Products & Services
High-yield hybrid seeds, research-based crop seeds, and various agricultural seed varieties.
Brand Portfolio
Indo Us Agriseeds, Indo Us Bio-Tech.
New Products/Services
The company is introducing new high-yield hybrid and research-based varieties; participation in global congresses suggests a focus on export-oriented seed technology.
Market Expansion
Expansion into global seed markets via the APSA Seed Congress 2025 held in Mumbai to connect with international partners.
Market Share & Ranking
Positioned as a leading DSIR-registered and NSE/BSE listed seed company in India.
Strategic Alliances
Collaborations with related parties like Indo US Agriseeds Pvt. Ltd. and Shree Patel Beej Nigam for production and distribution.
External Factors
Industry Trends
The industry is shifting toward biotech-enhanced and climate-resilient seeds. INDOUS is positioning itself as a technology-driven player by focusing on high-yield hybrids and global research trends.
Competitive Landscape
Competes with both domestic seed companies and multinational biotech firms in the hybrid seed segment.
Competitive Moat
The primary moat is the DSIR-registered R&D status and proprietary seed varieties, which provide a durable advantage through intellectual property and higher crop yields for farmers.
Macro Economic Sensitivity
Highly sensitive to agricultural GDP and rural income levels, which dictate the purchasing power of the primary consumer base (farmers).
Consumer Behavior
Farmers are increasingly shifting toward branded, high-yield research seeds over traditional varieties to ensure better ROI on farming inputs.
Geopolitical Risks
Trade barriers in global seed exports could impact the expansion plans showcased at the APSA Seed Congress.
Regulatory & Governance
Industry Regulations
Subject to Seed Act regulations, DSIR certification standards, and agricultural quality norms for hybrid seed production.
Environmental Compliance
The company complies with agro-based industry standards; specific ESG costs were not disclosed.
Taxation Policy Impact
The effective tax rate for H1 FY26 was approximately 2.67% (INR 22.43 Lakhs tax on INR 837.88 Lakhs PBT).
Legal Contingencies
No significant and material orders were passed by regulators, courts, or tribunals impacting the going concern status or future operations.
Risk Analysis
Key Uncertainties
Seasonal dependency and climate risk could impact seed production and sales by 15-20% in a poor monsoon year.
Geographic Concentration Risk
High concentration in Gujarat, with the registered office and primary operations based in Ahmedabad.
Third Party Dependencies
Significant reliance on related parties like Shree Patel Beej Nigam for operational arrangements.
Technology Obsolescence Risk
Risk of proprietary seed varieties being superseded by newer biotech innovations; mitigated by continuous R&D investment.
Credit & Counterparty Risk
Receivables quality is linked to the financial health of the agricultural distribution network.